News Release Details

Molecular Partners Publishes Invitation to Annual General Meeting 2018

March 21, 2018

Zurich-Schlieren, March 21, 2018. Molecular Partners AG (ticker: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies*, today published the invitation to the Annual General Meeting 2018.

The Annual General Meeting will be held on Wednesday, April 18, 2018, 2.00 pm CET (doors open at 1.30 pm), at the registered office of the company:
Molecular Partners AG, Wagistrasse 14, 5th floor, 8952 Schlieren, Switzerland

Link to the Invitation to the Annual General Meeting 2018 with the corresponding agenda items.

Link zur Einladung zur Generalversammlung 2018 mit den zugehörigen Traktandenpunkten.

Financial Calendar

  • April 18, 2018 – Annual General Meeting
  • April 26, 2018 – Q1 2018 Management Statement
  • August 30, 2018 – Publication of 2018 Half-year Results
  • November 01, 2018 – Q3 2018 Management Statement


About Molecular Partners AG

Molecular Partners AG is a clinical-stage biopharmaceutical company that is developing a new class of therapies known as DARPin® therapies. With a management team that includes many of the founding scientists, the company continues to attract talented individuals who share the passion to develop breakthrough medicines for serious diseases. Molecular Partners has compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on ophthalmology and oncology. The company establishes research and development partnerships with leading pharmaceutical companies and is backed by established biotech investors.

For more information regarding Molecular Partners AG, go to:


For further details, please contact:

Dr. Patrick Amstutz, CEO
Tel: +41 (0) 44 755 77 00

Andreas.Emmenegger, CFO
Tel: +41 (0) 44 755 77 00

Rolf Schläpfer
Tel: +41 (0) 43 344 42 42

Susan A. Noonan
S.A. Noonan Communications, LLC
Tel: +1 212 966 3650

*DARPin® is a registered trademark owned by Molecular Partners AG



This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Molecular Partners AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions.